Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...
How has the combination of antibody-drug conjugate and checkpoint inhibitors revolutionized treatment for patients with metastatic urothelial cancer? The clinical results from several trials suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results